{
    "clinical_study": {
        "@rank": "33585", 
        "arm_group": [
            {
                "arm_group_label": "Active Oral Orthotic Treatment", 
                "arm_group_type": "Experimental", 
                "description": "Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study."
            }, 
            {
                "arm_group_label": "Placebo Oral Orthotic Treatment", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Control participants will receive an identical sham splint to the active condition, but not adjusted to the recommended height for the given participant. Participants will be asked to wear the orthotic 24/7 for the duration of the study."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the feasibility of a trial on an oral orthotic for\n      reducing tic severity in children ages 7-17 years with Tourette syndrome (TS) or Chronic Tic\n      Disorder (CTD)."
        }, 
        "brief_title": "Proof of Concept Study of an Oral Orthotic to Reduce Tic Severity in Chronic Tic Disorder and Tourette Syndrome", 
        "condition": [
            "Tourette Syndrome", 
            "Chronic Tic Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Tic Disorders", 
                "Tics", 
                "Tourette Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is a 2 group, 2 week randomized controlled feasibility trial of an active vs sham\n      oral orthotic to reduce tic severity in children and adolescents ages 7-17 years.\n      Responders to acute phase treatment will be followed for 10 additional week (12 weeks total)\n      to assess intervention durability, safety and acceptability.  Non-responders to the sham\n      orthotic will be provided active treatment at the end of the 2 week acute phase. We aim to\n      assess and enroll 24 participants; twelve participants will receive an orthotic adjusted to\n      the appropriate therapeutic height, and twelve participants will receive an identical sham\n      orthotic, but not adjusted to the recommended height for the given participant."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 7-17 inclusive.\n\n          -  Presence of motor and/or vocal tics for at least 12 months.\n\n          -  Tics are of at least moderate clinical severity as evidenced by a Yale Global Tic\n             Severity score of 14 or higher for motor or vocal tics only and 22 or higher for\n             Tourette syndrome and present during the baseline assessment.\n\n          -  IQ estimate of 70 or higher\n\n          -  Comorbid disorder (e.g., ADHD, OCD, ODD) will be allowed provided that the tic\n             symptoms are of primary concern to parents and comorbid symptoms are not of\n             sufficient severity to require immediate treatment other than that provided by the\n             current study.\n\n          -  Pre-existing stable medication (see protocol for details), tic or otherwise, will\n             also be allowed provided the family agrees to refrain from med changes over the\n             course of the acute phase of the study\n\n          -  Sufficient command of the English language to participate in informed consent and\n             assessment procedures.\n\n          -  Agree for videotaping of study procedures\n\n          -  Clearance by treating dentist: Certification of good dental health provided by the\n             subjects current dentist prior to enrollment in the study\n\n        Exclusion Criteria:\n\n          -  Major psychiatric disorder at screening that would preclude full participation in\n             study procedures including psychosis, mania, depression, untreated combined type\n             ADHD, autism and pervasive developmental disorders.\n\n          -  Medication changes are planned during the acute and follow-up phase of treatment.\n\n          -  Other dental health problems that might interfere with the assessment, installation,\n             or wearing of orthotic device.\n\n          -  Does not consent to being videotaped"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "7 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02067819", 
            "org_study_id": "1208012905"
        }, 
        "intervention": [
            {
                "arm_group_label": "Active Oral Orthotic Treatment", 
                "intervention_name": "Active Orthotic Device", 
                "intervention_type": "Device", 
                "other_name": [
                    "Occlusal Splint", 
                    "Oral Orthotic", 
                    "Dental Orthotic", 
                    "Dental Appliance"
                ]
            }, 
            {
                "arm_group_label": "Placebo Oral Orthotic Treatment", 
                "intervention_name": "Sham Oral Orthotic", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Tourette's", 
            "Tic Disorder", 
            "Dental Appliance", 
            "Oral Orthotic", 
            "Mouthguard"
        ], 
        "lastchanged_date": "February 18, 2014", 
        "location": {
            "contact": {
                "email": "alk2021@med.cornell.edu", 
                "last_name": "Alex E Keller, BS", 
                "phone": "212-746-5930"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Weill Cornell Medical College"
            }, 
            "investigator": [
                {
                    "last_name": "Shannon Bennett, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Alex Keller, BS", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Justin Mohatt, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Proof of Concept Study of an Oral Orthotic to Reduce Tic Severity in Chronic Tic Disorder and Tourette Syndrome", 
        "overall_contact": {
            "email": "alk2021@med.cornell.edu", 
            "last_name": "Alex E Keller, B.S.", 
            "phone": "2127465930"
        }, 
        "overall_official": {
            "affiliation": "Weill Medical College of Cornell University", 
            "last_name": "John T Walkup, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Institutional Review Board: Weill Cornell Medical College"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The purpose of this study is to evaluate the feasibility of our procedures. It is therefore important to assess any and all  protocol to inform future studies.", 
                "measure": "Number of Protocol Deviations", 
                "safety_issue": "No", 
                "time_frame": "One Year"
            }, 
            {
                "description": "As this is a feasibility study, it will be important to understand the quantity and the nature of any and all adverse events.", 
                "measure": "Number of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "One Year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02067819"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Weill Medical College of Cornell University", 
            "investigator_full_name": "Shannon Bennett", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Weill Medical College of Cornell University", 
        "sponsors": {
            "collaborator": {
                "agency": "The Hindin Center", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Shannon Bennett", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}